Society for biomolecular sciences - 16th annual conference & exhibition - advancing the science of drug discovery.
The 16th annual conference of the Society for Biomolecular Sciences, held in Phoenix, AZ, USA, included topics covering new drug discovery efforts in the field of oncology research. This conference report highlights selected presentations on developing inhibitors of biochemical and cell-based targets, particularly PI3K and Hsp90; the effect of protein domain structure, inhibitor binding kinetics and phosphorylation state on inhibitor potency; and screening strategies for DNA repair, senescence and synthetic lethality. Investigational drugs discussed include GDC-0941 (Genentech Inc), NVP-AUY-922 (Novartis AG) and olaparib (AstraZeneca).
Napper
Andrew D
AD
Nemours Center for Childhood Cancer Research, 1701 Rockland Road, Wilmington, DE 19803, USA. napper@medsci.udel.edu
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D045744:Cell Line, Tumor; D015195:Drug Design; D055808:Drug Discovery; D004354:Drug Screening Assays, Antitumor; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D013678:Technology, Pharmaceutical
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors; D018841:HSP90 Heat-Shock Proteins; D000081082:Phosphoinositide-3 Kinase Inhibitors